General Partner at GV (formerly Google Ventures), investing in healthcare and life sciences, including oncology therapeutics and technologies. Krishna Yeshwant's investments in Foundation Medicine, Flatiron Health, ROME Therapeutics, and Xilis underscore his commitment to advancing breakthroughs in oncology. These companies are at the forefront of revolutionizing cancer diagnostics, treatment, and research. Yeshwant's support for these innovative ventures reflects his dedication to improving patient outcomes and driving progress in the field of oncology.